144 related articles for article (PubMed ID: 22802566)
21. Micro-SPET/CT and histology results of zoledronate treatment in a nude mouse lung adenocarcinoma skeletal metastases model: a pilot study.
Zhang Y; Cheng D; Shi H; Tan H; Wu B; Gu Y; Li B
Hell J Nucl Med; 2013; 16(3):240-1. PubMed ID: 24520579
[No Abstract] [Full Text] [Related]
22. A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid.
Kosaka T; Yamaki E; Mogi A; Kuwano H
Tumori; 2014; 100(2):e45-8. PubMed ID: 24852875
[TBL] [Abstract][Full Text] [Related]
23. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
[TBL] [Abstract][Full Text] [Related]
24. Lung adenocarcinoma presents with diffuse bone metastasis.
Mi J; Xu Q; Zhang Y
Thorac Cancer; 2021 Oct; 12(19):2628-2629. PubMed ID: 34423569
[No Abstract] [Full Text] [Related]
25. [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma].
Liu Y; Jiang Y; Gao Z; Wang X; Han B; Jiang L
Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):704-9. PubMed ID: 21924035
[TBL] [Abstract][Full Text] [Related]
26. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].
Yan X; Zhao X; Jiao S; Sun S; Wu L; Wu Z
Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):164-71. PubMed ID: 22429580
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
29. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
30. Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma.
Kaneda H; Okamoto I; Sakai K; Tanizaki J; Takeda M; Nishio K; Nakagawa K
Acta Oncol; 2012 Sep; 51(7):942-4. PubMed ID: 22283471
[No Abstract] [Full Text] [Related]
31. Cutaneous metastasis as the initial manifestation of lung adenocarcinoma.
Pantarotto M; Lombo L; Pereira H; Araújo A
J Bras Pneumol; 2011; 37(4):556-9. PubMed ID: 21881746
[TBL] [Abstract][Full Text] [Related]
32. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.
Bailon O; Chouahnia K; Augier A; Bouillet T; Billot S; Coman I; Ursu R; Belin C; Zelek L; Des Guetz G; Levy C; Carpentier AF; Morere JF
Neuro Oncol; 2012 Apr; 14(4):491-5. PubMed ID: 22362813
[TBL] [Abstract][Full Text] [Related]
33. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.
Hashisako M; Wakamatsu K; Ikegame S; Kumazoe H; Nagata N; Kajiki A
Tohoku J Exp Med; 2012 Oct; 228(2):163-8. PubMed ID: 23036980
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
[TBL] [Abstract][Full Text] [Related]
37. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
Sakhri L; Pinsolle J; Moro-Sibilot D; Pluchart H
J Med Case Rep; 2017 Sep; 11(1):262. PubMed ID: 28915906
[TBL] [Abstract][Full Text] [Related]
38. [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases].
Wang W; Shang L; Li X; Li J; Wen F; Liu J
Zhongguo Fei Ai Za Zhi; 2011 Jan; 14(1):54-7. PubMed ID: 21219833
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
